NCT04755088View on ClinicalTrials.gov

Surufatinib Renal Impairment Study

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 12, 2021

Primary Completion Date

August 21, 2021

Study Completion Date

August 21, 2021

Conditions
Renal Impairment
Interventions
DRUG

Surufatinib

Subjects to receive Surufatinib 300mg on Day 1

DRUG

Surufatinib

Subjects to receive Surufatinib 300mg on Day 1

Trial Locations (2)

32809

Orlando Clinical Research Center, Inc., Orlando

92780

Orange County Research Center, Tustin

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT04755088 - Surufatinib Renal Impairment Study | Biotech Hunter | Biotech Hunter